Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.
Mochida Pharmaceutical Dividend Announcement
• Mochida Pharmaceutical announced a semi annually dividend of ¥40.00 per ordinary share which will be made payable on 2025-06-01. Ex dividend date: 2025-03-28
• Mochida Pharmaceutical's trailing twelve-month (TTM) dividend yield is 2.42%
Mochida Pharmaceutical Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2025-03-28 | ¥40.00 | semi annually | 2025-06-01 |
2024-09-27 | ¥40.00 | semi annually | 2024-12-02 |
2024-03-28 | ¥40.00 | semi annually | |
2023-09-28 | ¥40.00 | semi annually | 2023-12-01 |
2023-03-30 | ¥40.00 | semi annually | 2023-06-30 |
2022-09-29 | ¥40.00 | semi annually | 2022-12-01 |
2022-03-30 | ¥40.00 | semi annually | 2022-06-30 |
2021-09-29 | ¥40.00 | semi annually | 2021-12-01 |
2021-03-30 | ¥40.00 | semi annually | 2021-06-30 |
2020-09-29 | ¥40.00 | semi annually | 2020-12-01 |
2020-03-30 | ¥40.00 | semi annually | 2020-06-29 |
2019-09-27 | ¥40.00 | semi annually | 2019-12-02 |
2019-03-27 | ¥180.00 | semi annually | 2019-06-28 |
2018-09-26 | ¥80.00 | semi annually | 2018-12-03 |
2018-03-28 | ¥97.50 | semi annually | 2018-06-29 |
2017-09-27 | ¥72.50 | semi annually | 2017-12-01 |
2017-03-29 | ¥100.00 | semi annually | 2017-06-30 |
2016-09-28 | ¥55.00 | semi annually | |
2016-03-29 | ¥82.50 | semi annually | |
2015-09-28 | ¥67.50 | semi annually | |
2015-03-27 | ¥75.00 | semi annually | |
2014-09-26 | ¥75.00 | semi annually | |
2014-03-27 | ¥15.00 | semi annually |
Mochida Pharmaceutical Dividend per year
Mochida Pharmaceutical Dividend growth
Mochida Pharmaceutical Dividend Yield
Mochida Pharmaceutical current trailing twelve-month (TTM) dividend yield is 2.42%. Interested in purchasing Mochida Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:
Mochida Pharmaceutical Financial Ratios
Mochida Pharmaceutical Dividend FAQ
Other factors to consider when evaluating Mochida Pharmaceutical as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Mochida Pharmaceutical stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Mochida Pharmaceutical's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Mochida Pharmaceutical publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Mochida Pharmaceutical distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Mochida Pharmaceutical are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Mochida Pharmaceutical sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Mochida Pharmaceutical distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Mochida Pharmaceutical declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Mochida Pharmaceutical's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Mochida Pharmaceutical's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.